Previous 10 | Next 10 |
Clinical Plan Includes Healthy Volunteers in New Zealand and OTC-Deficient Patients Across Several Sites in United States Investor Conference Call at 4:00 pm ET Today SAN DIEGO, April 13, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARC...
The FDA has signed off on a Phase 2 clinical trial evaluating intranasal administration of Biohaven Pharmaceutical Holding Company's (NYSE: BHVN ) migraine med vazegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, in COVID-19 patients with pulmonary complications who ne...
GMP-Manufactured Batch to be Delivered in June 2020 Human Dosing Expected to Begin in Summer 2020 SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, ...
Arcturus Therapeutics (NASDAQ: ARCT ) provides details about its strategy to rapidly learn about the safety and efficacy profile of its COVID-19 vaccine using Duke-NUS' genetic correlation system. More news on: Arcturus Therapeutics Holdings Inc., Healthcare stocks news, Read more .....
SAN DIEGO, March 27, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines and vaccines company, today provided details about the Company’s strategy to rapidly learn about the safety and efficacy profile of its C...
Stocks have plummeted across the board. We are going to go into a recession. Everyone is going to die. Or not. The simple fact is this too shall pass. For now, good firms with solid incoming cash flows, and bad firms with unserviceable debt and troubled cash flows are being treated roughly...
Gainers: OpGen (NASDAQ: OPGN ) +109% . More news on: OpGen, Inc., Blue Apron Holdings, Inc., Aytu BioScience, Inc., Stocks on the move, , Read more ...
Arcturus Therapeutics Holdings, Inc. (ARCT) Q4 2019 Earnings Conference Call March 11, 2020, 16:30 ET Company Participants Neda Safarzadeh - Director & Head, IR/Public Relations & Marketing Joseph Payne - Founder, President, CEO & Director Andrew Sassine - CFO & D...
Arcturus Therapeutics (NASDAQ: ARCT ): Q4 GAAP EPS of -$0.76 misses by $0.25 . More news on: Arcturus Therapeutics Holdings Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
IND Filed for Flagship Program ARCT-810 Coronavirus Vaccine Program Initiated Investor Conference Call at 4:30 pm ET Today SAN DIEGO, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines compa...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...